Crescent Biopharma (CBIO) Other Accumulated Expenses (2013 - 2024)
Crescent Biopharma (CBIO) posted quarterly Other Accumulated Expenses of $52948.0 for Q2 2024, up 156.16% year-over-year from $20670.0 in Q3 2023, and up 388.81% quarter-over-quarter from $10832.0 in Q1 2024.
Crescent Biopharma (CBIO) Other Accumulated Expenses (2013 - 2024) Analysis & Trends
Crescent Biopharma (CBIO) has reported Other Accumulated Expenses for 12 consecutive years, with $52948.0 the latest figure, recorded in Q2 2024.
- In Q2 2024, Other Accumulated Expenses rose 156.16% year-over-year to $52948.0; the TTM figure through Jun 2024 stood at $52948.0 (up 156.16% YoY), while the FY2022 annual figure was $42406.0, down 53.06% from the prior year.
- Other Accumulated Expenses climbed to $52948.0 in Q2 2024 per CBIO's latest filing, from $10832.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $260972.0 in Q3 2020 and bottomed at $10832.0 in Q1 2024.
- Historically, Other Accumulated Expenses has averaged $106627.4 across 5 years, with a median of $90342.0 in 2021.
- On a YoY basis, Other Accumulated Expenses climbed as much as 156.16% in 2024 and fell as far as 80.37% in 2024.
- Crescent Biopharma's Other Accumulated Expenses stood at $220469.0 in 2020, then tumbled by 59.02% to $90342.0 in 2021, then tumbled by 53.06% to $42406.0 in 2022, then sank by 61.19% to $16457.0 in 2023, then soared by 221.74% to $52948.0 in 2024.
- Business Quant data shows CBIO's Other Accumulated Expenses at $52948.0 in Q2 2024, $10832.0 in Q1 2024, and $16457.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Crescent Biopharma | 1.10 Bn | 933.02 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 52,948.00 |
| Mar 31, 2024 | 10,832.00 |
| Sep 30, 2023 | 16,457.00 |
| Jun 30, 2023 | 20,670.00 |
| Mar 31, 2023 | 55,190.00 |
| Dec 31, 2022 | 42,406.00 |
| Sep 30, 2022 | 59,336.00 |
| Jun 30, 2022 | 82,426.00 |
| Mar 31, 2022 | 109,895.00 |
| Dec 31, 2021 | 90,342.00 |
| Sep 30, 2021 | 163,538.00 |
| Jun 30, 2021 | 187,966.00 |
| Mar 31, 2021 | 106,898.00 |
| Dec 31, 2020 | 220,469.00 |
| Sep 30, 2020 | 260,972.00 |
| Jun 30, 2020 | 153,917.00 |
| Mar 31, 2020 | 178,403.00 |
| Dec 31, 2019 | 210,904.00 |
| Sep 30, 2019 | 143,620.00 |
| Jun 30, 2019 | 153,340.00 |